[Skip to Content]
[Skip to Content Landing]
December 28, 1994

Tacrine for Alzheimer's Disease-Reply

JAMA. 1994;272(24):1897-1898. doi:10.1001/jama.1994.03520240024024

In Reply.  —In response to Dr Wolferman and Dr Temianka, JAMA recognizes that pharmaceutical manufacturers conducting studies on drugs they manufacture have a vested interest in demonstrating efficacy of the drug. Conflicts of interest may be obvious, as in this case, or more subtle.1 Therefore, JAMA requires all authors to sign the financial disclosure statement2 and includes all pertinent information in a footnote as part of the article. However, simply because an individual or company has a conflict does not mean they cannot conduct legitimate research. One purpose of editing and peer review is to evaluate reports of studies for possible biases and flaws and select those with the best science. This study met that test. Specific criteria to assess the quality of drug studies in the literature were recently published by Cho and Bero.3Investigators increasingly must depend on nongovernmental funds to conduct research. We choose